Mac-2 binding protein glycosylation isomer as a novel serum biomarker for recurrence in hepatocellular carcinoma

doi:10.3748/wjg.v32.i5.113693

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 5

This Article

(57)

(41)

(0)

(639)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Gastroenterol. Feb 7, 2026; 32(5): 113693
Published online Feb 7, 2026. doi: 10.3748/wjg.v32.i5.113693

Full Size Figure Download Figure

Figure 1 PRISMA diagram of studies evaluated, excluded, and included in the meta-analysis. HCC: Hepatocellular carcinoma; M2BPGi: Mac-2 binding protein glycosylation isomer.

Citation: Stephens KR, Wilson M, Xu M, Gaskins JT, Genova G, Martin II RCG. Mac-2 binding protein glycosylation isomer as a novel serum biomarker for recurrence in hepatocellular carcinoma. World J Gastroenterol 2026; 32(5): 113693
URL: https://www.wjgnet.com/1007-9327/full/v32/i5/113693.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i5.113693

Stephens KR, Wilson M, Xu M, Gaskins JT, Genova G, Martin II RCG. Mac-2 binding protein glycosylation isomer as a novel serum biomarker for recurrence in hepatocellular carcinoma. World J Gastroenterol 2026; 32(5): 113693 [PMID: 41693972 DOI: 10.3748/wjg.v32.i5.113693]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.